RTCA

Summary

RTCA (RNA 3’-terminal phosphate cyclase, HGNC:17981) is a protein-coding gene on chromosome 1p21.2, encoding RNA 3’-terminal phosphate cyclase (O00442). Catalyzes the conversion of 3’-phosphate to a 2’,3’-cyclic phosphodiester at the end of RNA.

This gene encodes a member of the RNA 3’-phosphate cyclase family. The encoded protein plays a role in RNA metabolism by catalyzing the ATP-dependent conversion of the 3’-phosphate of RNA substrates to a 2’,3’-cyclic phosphodiester. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 8634 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 90 total
• MANE Select transcript: NM_003729

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17981
Approved symbol	RTCA
Name	RNA 3’-terminal phosphate cyclase
Location	1p21.2
Locus type	gene with protein product
Status	Approved
Aliases	RPC, RTC1
Ensembl gene	ENSG00000137996
Ensembl biotype	protein_coding
OMIM	611286
Entrez	8634

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 10 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000260563, ENST00000370126, ENST00000370128, ENST00000483474, ENST00000498617, ENST00000881959, ENST00000881960, ENST00000927400, ENST00000927401, ENST00000958304, ENST00000958305, ENST00000958306

RefSeq mRNA: 2 — MANE Select: NM_003729 NM_001130841, NM_003729

CCDS: CCDS44178, CCDS768

Canonical transcript exons

ENST00000370128 — 11 exons

Exon	Start	End
ENSE00000831307	100274824	100274965
ENSE00000831308	100275599	100275723
ENSE00001166889	100287099	100287203
ENSE00001166896	100285228	100285322
ENSE00001166905	100277258	100277316
ENSE00001167849	100266216	100266420
ENSE00001196477	100291403	100292769
ENSE00003514174	100268152	100268295
ENSE00003537387	100266524	100266624
ENSE00003607452	100273394	100273452
ENSE00003618171	100270557	100270680

Expression profiles

Bgee: expression breadth ubiquitous, 296 present calls, max score 96.44.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 52.2743 / max 487.5155, expressed in 1827 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
4219	48.6806	1827
4220	2.3511	1161
4218	0.7448	488
4221	0.4978	276

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	96.44	gold quality
esophagus squamous epithelium	UBERON:0006920	94.91	gold quality
duodenum	UBERON:0002114	94.40	gold quality
epithelium of esophagus	UBERON:0001976	94.16	gold quality
dorsal root ganglion	UBERON:0000044	93.59	gold quality
amniotic fluid	UBERON:0000173	93.49	gold quality
heart right ventricle	UBERON:0002080	92.80	gold quality
jejunum	UBERON:0002115	92.75	gold quality
sural nerve	UBERON:0015488	92.43	gold quality
mucosa of sigmoid colon	UBERON:0004993	92.15	gold quality
colonic mucosa	UBERON:0000317	92.14	gold quality
biceps brachii	UBERON:0001507	92.11	gold quality
body of pancreas	UBERON:0001150	92.03	gold quality
corpus epididymis	UBERON:0004359	91.87	gold quality
pons	UBERON:0000988	91.80	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.59	gold quality
adrenal tissue	UBERON:0018303	91.54	gold quality
gastrocnemius	UBERON:0001388	91.45	gold quality
calcaneal tendon	UBERON:0003701	91.43	gold quality
nephron tubule	UBERON:0001231	91.37	gold quality
muscle of leg	UBERON:0001383	91.29	gold quality
oral cavity	UBERON:0000167	91.17	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	90.97	gold quality
heart left ventricle	UBERON:0002084	90.93	gold quality
cardiac ventricle	UBERON:0002082	90.84	gold quality
mucosa of transverse colon	UBERON:0004991	90.80	gold quality
cortical plate	UBERON:0005343	90.72	gold quality
rectum	UBERON:0001052	90.70	gold quality
tibia	UBERON:0000979	90.68	gold quality
tendon	UBERON:0000043	90.64	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.73

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

62 targeting RTCA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-4671-3P	99.88	72.46	1045
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311

Literature-anchored findings (GeneRIF, showing 2)

• Rtc1 forms a stable binary complex with a 3’-phosphate terminated RNA, but not with an identical 3’-OH terminated RNA (PMID:19690099)
• CNP and RtcA fine-tune XBP1 output during ER stress (PMID:30355738)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	rtca	ENSDARG00000002215
mus_musculus	Rtca	ENSMUSG00000000339
rattus_norvegicus	Rtca	ENSRNOG00000014575
drosophila_melanogaster	Rtca	FBGN0025630

Paralogs (1): RCL1 (ENSG00000120158)

Protein

Protein identifiers

RNA 3’-terminal phosphate cyclase — O00442 (reviewed: O00442)

Alternative names: RNA terminal phosphate cyclase domain-containing protein 1

All UniProt accessions (2): A6NIC1, O00442

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the conversion of 3’-phosphate to a 2’,3’-cyclic phosphodiester at the end of RNA. The mechanism of action of the enzyme occurs in 3 steps: (A) adenylation of the enzyme by ATP; (B) transfer of adenylate to an RNA-N3’P to produce RNA-N3’PP5’A; (C) and attack of the adjacent 2’-hydroxyl on the 3’-phosphorus in the diester linkage to produce the cyclic end product. Likely functions in some aspects of cellular RNA processing. Function plays an important role in regulating axon regeneration by inhibiting central nervous system (CNS) axon regeneration following optic nerve injury.

Subcellular location. Nucleus. Nucleoplasm.

Tissue specificity. Ubiquitous.

Similarity. Belongs to the RNA 3’-terminal cyclase family. Type 1 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
O00442-1	1	yes
O00442-2	2

RefSeq proteins (2): NP_001124313, NP_003720* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000228	RNA3’_term_phos_cyc	Family
IPR013791	RNA3’-term_phos_cycl_insert	Domain
IPR013792	RNA3’P_cycl/enolpyr_Trfase_a/b	Homologous_superfamily
IPR017770	RNA3’_term_phos_cyc_type_1	Family
IPR020719	RNA3’_term_phos_cycl-like_CS	Conserved_site
IPR023797	RNA3’_phos_cyclase_dom	Domain
IPR036553	RPTC_insert	Homologous_superfamily
IPR037136	RNA3’_phos_cyclase_dom_sf	Homologous_superfamily

Pfam: PF01137, PF05189

Enzyme classification (BRENDA):

• EC 6.5.1.4 — RNA 3’-terminal-phosphate cyclase (ATP) (BRENDA: 25 organisms, 55 substrates, 8 inhibitors, 9 Km, 1 kcat entries)

Substrate kinetics (BRENDA)

3 substrates with measured Km, best-characterized 3. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0017–0.02	5
ATPGAMMAS	0.006	2
GTP	0.1–0.2	2

Catalyzed reactions (Rhea), 1 shown:

• a 3’-end 3’-phospho-ribonucleotide-RNA + ATP = a 3’-end 2’,3’-cyclophospho-ribonucleotide-RNA + AMP + diphosphate (RHEA:23976)

UniProt features (10 total): binding site 6, chain 1, active site 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O00442-F1	95.90	0.95

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 320 (tele-amp-histidine intermediate)

Ligand- & substrate-binding residues (6): 104; 131; 294; 297; 298; 320

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 169 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOBP_REGENERATION, GOBP_NEUROGENESIS, GOBP_RESPONSE_TO_AXON_INJURY, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP, PATIL_LIVER_CANCER, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, GOBP_REGULATION_OF_RESPONSE_TO_WOUNDING, GNF2_XRCC5, GOBP_REGULATION_OF_RESPONSE_TO_STRESS, GOBP_REGULATION_OF_NEURON_PROJECTION_REGENERATION, GOBP_NEGATIVE_REGULATION_OF_CELL_PROJECTION_ORGANIZATION

GO Biological Process (2): RNA processing (GO:0006396), negative regulation of optical nerve axon regeneration (GO:1905592)

GO Molecular Function (7): RNA binding (GO:0003723), RNA-3’-phosphate cyclase activity (GO:0003963), ATP binding (GO:0005524), nucleotide binding (GO:0000166), catalytic activity (GO:0003824), protein binding (GO:0005515), ligase activity (GO:0016874)

GO Cellular Component (2): nucleus (GO:0005634), nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
gene expression	1
RNA biosynthetic process	1
primary metabolic process	1
negative regulation of axon regeneration	1
optical nerve axon regeneration	1
regulation of optical nerve axon regeneration	1
nucleic acid binding	1
cyclase activity	1
ligase activity, forming phosphoric ester bonds	1
catalytic activity, acting on RNA	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
molecular_function	1
binding	1
catalytic activity	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2519 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RTCA	BMS1	Q14692	853
RTCA	RTCB	Q9Y3I0	851
RTCA	DPH5	Q9H2P9	614
RTCA	LRRC39	Q96DD0	609
RTCA	TRPT1	Q86TN4	605
RTCA	DBT	P11182	557
RTCA	ZBTB8OS	Q8IWT0	547
RTCA	TRMT13	Q9NUP7	512
RTCA	FCF1	Q9Y324	478
RTCA	SLC35H1	Q9NQQ7	457
RTCA	SLC30A7	Q8NEW0	455
RTCA	RO60	P10155	446
RTCA	FAM98B	Q52LJ0	430
RTCA	GGN	Q86UU5	425
RTCA	FPGT	O14772	423
RTCA	GPR88	Q9GZN0	423

IntAct

80 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
LAMP3	METTL15	psi-mi:“MI:0914”(association)	0.530
Sass6	MACF1	psi-mi:“MI:0914”(association)	0.350
FOXL2	RTCA	psi-mi:“MI:0914”(association)	0.350
FOXQ1	ARHGAP10	psi-mi:“MI:0914”(association)	0.350
FOXS1	DDX39A	psi-mi:“MI:0914”(association)	0.350
JUN		psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
CAND1	GTPBP10	psi-mi:“MI:0914”(association)	0.350
USP45	RTCA	psi-mi:“MI:0914”(association)	0.350
PRKD1	MYO1C	psi-mi:“MI:0914”(association)	0.350
ZDHHC5	HACD3	psi-mi:“MI:0914”(association)	0.350
TAGLN	LOC392647	psi-mi:“MI:0914”(association)	0.350
ARID1B	RTCA	psi-mi:“MI:0914”(association)	0.350
ITM2B	ILVBL	psi-mi:“MI:0914”(association)	0.350
OSTM1	ILVBL	psi-mi:“MI:0914”(association)	0.350
PRKY	METTL15	psi-mi:“MI:0914”(association)	0.350
HOXC5	PDLIM1	psi-mi:“MI:0914”(association)	0.350
GORASP1	RTCA	psi-mi:“MI:0914”(association)	0.350
CNTN2	RTCA	psi-mi:“MI:0914”(association)	0.350
ZNF695	RTCA	psi-mi:“MI:0914”(association)	0.350
PAEP	RTCA	psi-mi:“MI:0914”(association)	0.350
HNRNPCL2	SMCHD1	psi-mi:“MI:0914”(association)	0.350
RTCA	NDUFA4	psi-mi:“MI:0914”(association)	0.350
	RTCA	psi-mi:“MI:0914”(association)	0.350
	POLRMT	psi-mi:“MI:0914”(association)	0.350

BioGRID (146): HNRNPH1 (Co-fractionation), RTCA (Affinity Capture-MS), RTCA (Affinity Capture-MS), RTCA (Affinity Capture-MS), RTCA (Affinity Capture-MS), RTCA (Affinity Capture-MS), RTCA (Affinity Capture-MS), RTCA (Affinity Capture-MS), RTCA (Affinity Capture-MS), RPL21 (Affinity Capture-MS), FBL (Affinity Capture-MS), RPL23A (Affinity Capture-MS), RPL18A (Affinity Capture-MS), DDX21 (Affinity Capture-MS), RTCA (Affinity Capture-MS)

ESM2 similar proteins: A2RVK7, A2X0Q3, A6QLJ3, O00442, O23617, O81147, O81852, P0CT46, P31754, P37142, P48605, P49080, P49368, P80318, Q01415, Q06265, Q14181, Q2HJ88, Q2KHU3, Q3SWZ4, Q3T0K2, Q4QR75, Q4R3J0, Q4R963, Q5NVF9, Q5R6J8, Q5R7P3, Q5RCW2, Q5RGJ5, Q5XJQ5, Q69LE7, Q6P502, Q6STH5, Q6YXZ7, Q7YRA3, Q84T68, Q8C3X4, Q8GZQ3, Q8K1R3, Q8N442

Diamond homologs: A0B532, A1AGU3, A1RSJ7, A2BN21, A3DN24, A3MXQ7, A4XRJ0, A4YEC3, A7ZSU9, A8A5M8, A8A9W2, A8MAV7, B0R414, B1IP46, B1L6E9, B1LI80, B1X765, B1YDJ1, B2IWJ8, B2U3M8, B4TKU5, B5F8N4, B5R378, B5R7J6, B5YTX2, B6YSJ5, B7KCF3, B7L4U9, B7LSC2, B7M2I0, B7MDP5, B7N1J7, B7NE24, B7NMI4, B7UKC4, B7V0C8, B8D680, C0Q0J3, C3MKC1, C3MU91

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 80 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Peptide chain elongation	10	23.5×	1e-09
Viral mRNA Translation	10	23.5×	1e-09
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	10	23.2×	1e-09
Selenocysteine synthesis	10	22.3×	1e-09
Eukaryotic Translation Termination	10	22.3×	1e-09
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	10	21.8×	1e-09
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA	10	21.8×	1e-09
Formation of a pool of free 40S subunits	10	20.7×	1e-09

GO biological processes:

GO term	Partners	Fold	FDR
cytoplasmic translation	11	28.3×	6e-11
translation	10	14.3×	4e-07

Disease & clinical

Clinical variants and AI predictions

ClinVar

90 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	63
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1801 predictions. Top by Δscore:

Variant	Effect	Δscore
1:100266417:AGGGG:A	donor_loss	1.0000
1:100266418:GGG:G	donor_gain	1.0000
1:100266419:GG:G	donor_gain	1.0000
1:100266419:GGG:G	donor_gain	1.0000
1:100266420:GG:G	donor_gain	1.0000
1:100266420:GGT:G	donor_loss	1.0000
1:100266421:G:GA	donor_loss	1.0000
1:100266421:G:GG	donor_gain	1.0000
1:100266422:T:A	donor_loss	1.0000
1:100266618:GCC:G	donor_gain	1.0000
1:100266621:TGAGG:T	donor_loss	1.0000
1:100266623:AGGT:A	donor_loss	1.0000
1:100266624:GGTAA:G	donor_loss	1.0000
1:100266625:G:A	donor_loss	1.0000
1:100266626:T:A	donor_loss	1.0000
1:100268135:A:AG	acceptor_gain	1.0000
1:100268136:G:GG	acceptor_gain	1.0000
1:100268167:T:TA	acceptor_gain	1.0000
1:100270556:GGA:G	acceptor_gain	1.0000
1:100270556:GGAGT:G	acceptor_gain	1.0000
1:100270605:T:A	acceptor_gain	1.0000
1:100273388:TTTCA:T	acceptor_loss	1.0000
1:100273389:TTCA:T	acceptor_loss	1.0000
1:100273391:CA:C	acceptor_loss	1.0000
1:100273392:A:AG	acceptor_gain	1.0000
1:100273392:A:T	acceptor_loss	1.0000
1:100273393:G:GG	acceptor_gain	1.0000
1:100274820:ATAGG:A	acceptor_gain	1.0000
1:100275592:A:AG	acceptor_gain	1.0000
1:100275596:TA:T	acceptor_loss	1.0000

AlphaMissense

2376 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:100274826:G:A	G159E	0.999
1:100275623:G:C	A214P	0.998
1:100285248:G:A	G274R	0.998
1:100285248:G:C	G274R	0.998
1:100285249:G:A	G274E	0.998
1:100285260:G:C	A278P	0.998
1:100285318:A:C	D297A	0.998
1:100285318:A:T	D297V	0.998
1:100287162:C:G	H320D	0.998
1:100268158:A:C	Q51H	0.997
1:100268158:A:T	Q51H	0.997
1:100268292:C:A	A96E	0.997
1:100270558:A:C	S98R	0.997
1:100270560:T:A	S98R	0.997
1:100270560:T:G	S98R	0.997
1:100270568:T:C	L101P	0.997
1:100270637:G:A	G124E	0.997
1:100270644:T:A	N126K	0.997
1:100270644:T:G	N126K	0.997
1:100274825:G:A	G159R	0.997
1:100274825:G:C	G159R	0.997
1:100274847:G:A	G166D	0.997
1:100275717:G:A	G245E	0.997
1:100277266:C:A	A250D	0.997
1:100285261:C:A	A278D	0.997
1:100285317:G:C	D297H	0.997
1:100287164:T:A	H320Q	0.997
1:100287164:T:G	H320Q	0.997
1:100266540:G:C	R21T	0.996
1:100270633:G:C	G123R	0.996

dbSNP variants (sampled 300 via entrez): RS1000150682 (1:100280849 A>G), RS1000162035 (1:100281423 A>G), RS1000171084 (1:100270214 T>G), RS1000487267 (1:100282517 T>G), RS1000541523 (1:100268926 C>T), RS1000594813 (1:100275143 C>A,T), RS1000912896 (1:100269049 A>C,G), RS1000929471 (1:100287801 T>C), RS1000961809 (1:100264338 T>C), RS1001128756 (1:100270155 C>T), RS1001163737 (1:100279762 A>T), RS1001165586 (1:100281307 G>A), RS1001420737 (1:100276381 T>C), RS1001484497 (1:100281558 A>G), RS1001501670 (1:100265121 T>C)

Disease associations

OMIM: gene MIM:611286 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002337_70	Amyotrophic lateral sclerosis (sporadic)	9.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, decreases expression, increases abundance	3
Valproic Acid	increases expression, affects expression	3
cobaltous chloride	increases expression	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Arsenic	affects methylation, increases abundance, increases expression	2
Cyclosporine	increases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
dicrotophos	decreases expression	1
bisphenol A	affects expression	1
sodium arsenate	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
nutlin 3	increases secretion, affects cotreatment	1
ICG 001	increases expression	1
bisphenol B	increases expression	1
abrine	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
NSC 689534	increases expression, affects binding	1
Resveratrol	affects cotreatment, increases expression	1
Copper	affects binding, increases expression	1
Dactinomycin	affects cotreatment, increases secretion	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ivermectin	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Quercetin	decreases expression	1
Rotenone	decreases expression	1
Thiram	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.